Marginal Zone Lymphoma (MZL)
13
6
7
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
15.4%
2 terminated out of 13 trials
50.0%
-36.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (13)
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
REal World Data in LYmphoma and Survival in Adults
Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0